Results 151 to 160 of about 121,777 (350)

HOME INTRAVENOUS IMMUNOGLOBULIN THERAPY

The Lancet, 1988
Chapel, H, Brennan, V
openaire   +3 more sources

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE) [PDF]

, 2015
Michael Absoud, Jonathan Gadian, Jennifer Hellier, P A Brex, Olga Ciccarelli, Gavin Giovannoni, Joanna Kelly, Paul McCrone, Caroline Murphy, Jacqueline Palace, Andrew Pickles, Mike Pike, Neil P. Robertson, A. Jacob, Ming Lim   +14 more
openalex   +1 more source

A-45-Year-Old Female, ABO Matched Living Related Kidney Transplant Recipient, Treatment Completed Hepatitis C Infection, Who Received Anti-Thymocyte Globulin as Induction Therapy Developed Pancytopenia and Acute Antibody Mediated Rejection Recovered with Plasmapheresis, Intravenous Immunoglobulin and Rituximab: Balancing Efficacy, Safety, and Cost! [PDF]

, 2023
Khin Phyu Pyar
openalex   +1 more source

Thrombotic Thrombocytopenic Purpura, Moschcowitz Syndrome [PDF]

, 2001
The authors present a case of a 16-year-old boy, who was referred to the hospital due to thrombocytopenia, anemia, proteinuria and hyperbilirubinemia. Based on the clinical picture and the laboratory data, thrombotic thrombocytopenic purpura (TTP) was ...
Czinyéri, Judit, Garami, Miklós, Kovács, Gábor, Müller, Judit, Sasvári, Ildikó   +4 more
core  

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

Ascites circRNA ASCOR Drives Platinum Resistance of High‐Grade Serous Ovarian Cancer by Facilitating RPA1 Nuclear Translocation

Advanced Science, EarlyView.
High‐grade serous ovarian carcinoma (HGSOC) is plagued by platinum resistance, with malignant ascites closely linked to poor outcomes. Here, we identify ASCOR, a circRNA enriched in ascites small extracellular vesicles (sEVs) from platinum‐resistant HGSOC patients, as a predictor of poor survival. ASCOR enhances platinum resistance in vitro and in vivo
Hanyuan Liu, Chenchen Zhu, Xuelin Yao, Yi Liu, Jing Zhu, Yuebo Li, Hanjie Xu, Cheng Peng, Ge Shan, Liang Chen, Ying Zhou   +10 more
wiley   +1 more source

A Dual‐Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor‐Associated Osteolysis Restoration via Sequential Release

Advanced Science, EarlyView.
The versatile CaO2@CuMOF@HAP nanohybrid demonstrates an outstanding MMP9/pH‐triggered release performance for sequential release of osteogenic growth peptide into deep‐seated tumor‐infiltrated bone destruction areas and dual ions into tumor cells, enabling efficient tumor‐associated osteolysis restoration and tumor elimination for more comprehensive ...
Lan Liu, Han‐Zhe Liu, Zhe‐Nan Liu, Tong Wang, Li‐Li Yu, Qiu‐Jing Li, Zi‐Yi Chen, Guo‐Feng Luo, Zheng‐Jun Shang   +8 more
wiley   +1 more source

Cardiovascular involvement in Kawaski Disease [PDF]

, 2005
This article contains a case report of a 19 month old child with Kawasaki Disease who developed bilateral giant coronary artery aneurysms.peer ...
Chintala, Kavitha, Forbes, T.J., Reddy, S.V.   +2 more
core  

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source